Li J Y, Boado R J, Pardridge W M
Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095-1682, USA.
J Cereb Blood Flow Metab. 2001 Jan;21(1):61-8. doi: 10.1097/00004647-200101000-00008.
The blood-brain barrier (BBB) is formed by the brain microvascular endothelium, and the unique transport properties of the BBB are derived from tissue-specific gene expression within this cell. The current studies developed a gene microarray approach specific for the BBB by purifying the initial mRNA from isolated rat brain capillaries to generate tester cDNA. A polymerase chain reaction-based subtraction cloning method, suppression subtractive hybridization (SSH), was used, and the BBB cDNA was subtracted with driver cDNA produced from mRNA isolated from rat liver and kidney. Screening 5% of the subtracted tester cDNA resulted in identification of 50 gene products and more than 80% of those were selectively expressed at the BBB; these included novel gene sequences not found in existing databases, ESTs, and known genes that were not known to be selectively expressed at the BBB. Genes in the latter category include tissue plasminogen activator, insulin-like growth factor-2, PC-3 gene product, myelin basic protein, regulator of G protein signaling 5, utrophin, IkappaB, connexin-45, the class I major histocompatibility complex, the rat homologue of the transcription factors hbrm or EZH1, and organic anion transporting polypeptide type 2. Knowledge of tissue-specific gene expression at the BBB could lead to new targets for brain drug delivery and could elucidate mechanisms of brain pathology at the microvascular level.
血脑屏障(BBB)由脑微血管内皮细胞形成,BBB独特的转运特性源于该细胞内组织特异性基因的表达。目前的研究通过从分离的大鼠脑毛细血管中纯化初始mRNA以生成测试者cDNA,开发了一种针对BBB的基因微阵列方法。使用了基于聚合酶链反应的消减克隆方法——抑制性消减杂交(SSH),用从大鼠肝脏和肾脏分离的mRNA产生的驱动者cDNA对BBB cDNA进行消减。对5%的消减测试者cDNA进行筛选,鉴定出50种基因产物,其中80%以上在BBB处选择性表达;这些包括在现有数据库、EST中未发现的新基因序列,以及未知在BBB处选择性表达的已知基因。后一类基因包括组织纤溶酶原激活物、胰岛素样生长因子-2、PC-3基因产物、髓鞘碱性蛋白、G蛋白信号调节因子5、肌动蛋白、IkappaB、连接蛋白-45、I类主要组织相容性复合体、转录因子hbrm或EZH1的大鼠同源物,以及2型有机阴离子转运多肽。了解BBB处的组织特异性基因表达可能会为脑内药物递送带来新的靶点,并可能阐明微血管水平上的脑病理机制。